Skip to content

Study · In vitro (cells) · 2021

2 results

Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.

Chen DY, Su PJ, See LC, Liu JR, Chuang CK, Pang ST, Tseng CN, Chen SW, Hsieh IC, Chu PH, Lin YC, Hsu CL and 5 more

Show all authors

Chang JW, Lin MS, Pang JS, Hsieh MJ, Huang WK

The Prostate1 Jul 2021Cited by 15 (Europe PMC)

PMID34196430 (opens in a new tab)DOI10.1002/pros.24187 (opens in a new tab)PepBankPUB-34196430
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In THP-1 differentiated macrophages, degarelix did not significantly increase MMP-9 activity, whereas leuprolide did.

    In plain wordsIn cells, degarelix did not significantly increase MMP-9 activity, whereas leuprolide did.

    Peptide
    Degarelix
    Outcome
    No significant changeMMP-9 activity
    Study

    humann: not reported in source

    THP-1 differentiated macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the in vitro study, leuprolide, but not degarelix, significantly increased the expression of MMP-9 activity and the invasive ability of THP-1 differentiated macrophages through gelatin zymography and the matrix invasion assay, respectively.
    1 context sentence
    Summary · context
    Furthermore, we conducted an in vitro study to investigate the effect of a GnRHa (leuprolide) or a GnRH antagonist (degarelix) on matrix metalloproteinase-9 (MMP-9) expression and invasion ability in THP-1 differentiated macrophages.
  2. 02LabIn vitro (cells)Mechanism

    In THP-1 differentiated macrophages, degarelix did not significantly increase invasive ability, whereas leuprolide did.

    In plain wordsIn cells, degarelix did not significantly increase invasive ability, whereas leuprolide did.

    Peptide
    Degarelix
    Outcome
    No significant changeMacrophage invasive ability
    Study

    humann: not reported in source

    THP-1 differentiated macrophages
    Outcome group
    Receptor activity and mechanism · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In the in vitro study, leuprolide, but not degarelix, significantly increased the expression of MMP-9 activity and the invasive ability of THP-1 differentiated macrophages through gelatin zymography and the matrix invasion assay, respectively.
    1 context sentence
    Summary · context
    Furthermore, we conducted an in vitro study to investigate the effect of a GnRHa (leuprolide) or a GnRH antagonist (degarelix) on matrix metalloproteinase-9 (MMP-9) expression and invasion ability in THP-1 differentiated macrophages.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.